Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 7/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.35 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27392700 | 0.84 | CDK1 (0.43) | CDK1YTHDC1ADORA2AADORA1CCNB1 | |
| SCHEMBL21703036 | 0.80 | CDK1 (0.47) | CDK1YTHDC1ADORA2AADORA1CCNB1 | |
| SCHEMBL25876344 | 0.80 | CDK1 (0.66) | CDK1YTHDC1ADORA2AADORA1CCNB1 | |
| SCHEMBL16481592 | 0.80 | CDK1 (0.43) | CDK1YTHDC1ADORA2AADORA1CCNB1 | |
| SCHEMBL7289687 | 0.80 | CDK1 (0.51) | CDK1YTHDC1ADORA2AADORA1CCNB1 | |
| SCHEMBL10148680 | 0.80 | CDK1 (0.57) | CDK1YTHDC1ADORA2AADORA1CCNB1 | |
| SCHEMBL4402870 | 0.80 | CDK1 (0.66) | CDK1YTHDC1ADORA2AADORA1CCNB1 | |
| SCHEMBL18232306 | 0.78 | — | — | |
| SCHEMBL25028478 | 0.77 | YTHDC1 (0.50) | CDK1YTHDC1ADORA2AADORA1CCNB1 | |
| SCHEMBL14441699 | 0.77 | CDK1 (0.41) | CDK1YTHDC1ADORA2AADORA1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119117-A1 | MODIFIED 5' CAP FOR MRNA AND METHODS OF USE THEREOF | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-9605018-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-9278990-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150141363-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-05-21 | — | — | US | disclosed |
| US-9012427-B2 | Pharmaceutical combinations comprising a thionucleotide analog | ALIOS BIOPHARMA, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8980865-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130190320-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120178767-A1 | TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS | GILEAD CALISTOGA LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120149657-A1 | 2'-FLUORO ARABINO NUCLEOSIDES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (AL) | 2012-06-14 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-7671036-B2 | Positively-charged peptide nucleic acid analogs with improved properties | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2010-03-02 | — | — | US | disclosed |
| US-7572898-B2 | Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonate and use thereof for making a beta nucleoside | SCINOPHARM TAIWAN, LTD. (TW) | 2009-08-11 | — | — | US | disclosed |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | CDK1 1056/4885YTHDC1 4760/4885ADORA2A 2554/4885 |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | CDK1 59/4885YTHDC1 4549/4885ADORA2A 1150/4885 |
| US-20120178767-A1 | TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS | PYGL, PRKCZ, PHKG1 | CDK1 464/4885YTHDC1 4765/4885ADORA2A 4199/4885 |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | HSP90B1, HSPBP1, HSP90AB2P | CDK1 780/4885YTHDC1 2643/4885ADORA2A 1000/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | CDK1 1837/4885YTHDC1 2073/4885ADORA2A 252/4885 |
| US-20120149657-A1 | 2'-FLUORO ARABINO NUCLEOSIDES AND USE THEREOF | SLC29A2, DUT, SLC29A1 | CDK1 1985/4885YTHDC1 394/4885ADORA2A 55/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | CDK1 1837/4885YTHDC1 2073/4885ADORA2A 252/4885 |
| US-20150141363-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | CDK1 1837/4885YTHDC1 2073/4885ADORA2A 252/4885 |
| US-20130190320-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ERBB2, EGFR, ERBB3 | CDK1 250/4885YTHDC1 4778/4885ADORA2A 2012/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | CDK1 2666/4885YTHDC1 334/4885ADORA2A 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.